RFA-HL-26-015-Full-Announcement.html

This document is a Request for Applications (RFA) for the NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional).

The RFA invites small businesses to submit SBIR grant applications to support later stage research and development (Phase IIB) for promising projects previously funded by SBIR or STTR Phase II awards. The targeted projects must address rare diseases or young pediatric populations and require eventual federal regulatory approval/clearance. The goal is to assist applicants in pursuing the next milestones necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors/strategic partners, including patient advocacy organizations. Proposed projects must be relevant to the NHLBI mission. The funding opportunity is assigned to several NIH grant programs related to lung, cardiovascular, blood, and sleep disorders research. The funding instrument is a grant, and the applicant type is limited to small businesses.